Submission for OMB Review; 30-Day Comment Request Surveys and Interviews To Support an Evaluation of the Innovative Molecular Analysis Technologies (IMAT) Program (NCI), 12487-12488 [2015-05298]

Download as PDF 12487 Federal Register / Vol. 80, No. 45 / Monday, March 9, 2015 / Notices TABLE 2—ESTIMATED ANNUAL REPORTING BURDEN 1 One-time (initial) burden ...................................................... Burden from future review ................................................... 1 There 1 1 Average burden per respondent Total annual responses 1 1 1 1 Total hours 80 26 80 26 are no capital costs or operating costs associated with the collection of information. Description of Respondents for Reporting: The final regulation on BSE (73 FR 22720) included a provision that exempts cattle materials prohibited in animal feed (CMPAF) from designated countries from the prohibition on its use in animal feed. A foreign country seeking this designation will submit a written request to FDA that includes a variety of information about the country’s BSE status (§ 589.2001(f)). During the past 6 years, FDA received 2 requests from countries to be exempted from CMPAF restrictions. One-Time (Initial) Reporting Burden There is a one-time burden to countries that apply to FDA seeking to be designated as not subject to restrictions applicable to CMPAF. We estimate that each country that applies for an exclusion will spend 80 hours putting information together to submit to FDA. Table 2 row 1 presents the onetime burden for the exclusion. (See final BSE regulation at 73 FR 22754). Recurring Burden Countries that successfully petition FDA to be designated as exempt from certain BSE-related restrictions applicable to animal feed will be subject to future review by FDA to ensure that their designation remains appropriate. As part of this process, FDA may ask designated countries from time-to-time to confirm that their BSE situation and the information submitted by them in support of their original application remains unchanged. We assume it will take FDA and the designated country undergoing a review in the future about one third the time and effort it did when the information was submitted. Table 2 row 2 presents the expected recurring burden. mstockstill on DSK4VPTVN1PROD with NOTICES Number of responses per respondent Number of respondents 21 CFR section 589.2001(f) Dated: March 2, 2015. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2015–05356 Filed 3–6–15; 8:45 am] BILLING CODE 4164–01–P VerDate Sep<11>2014 18:04 Mar 06, 2015 Jkt 235001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Center for Advancing Translational Sciences; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Center for Advancing Translational Sciences Special Emphasis Panel Small Business Innovation Research (SBIR). Date: March 31, 2015. Time: 8:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817. Contact Person: Rahat Khan, Ph.D., Scientific Review Officer, Office of Scientific Review, National Center for Advancing Translational Sciences, 6701 Democracy Blvd., Rm 1078, Bethesda, MD 20892, 301– 894–7319, khanr2@csr.nih.gov. Name of Committee: National Center for Advancing Translational Sciences Special Emphasis Panel CTSA Meeting 1. Date: April 8–9, 2015. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Hilton Washington/Rockville 1750 Rockville Pike, Rockville, MD 20852. Contact Person: Carol Lambert, Ph.D., Acting Deputy Director, Office of Grants Management & Scientific Review, National Center for Advancing Translational Sciences (NCATS) National Institutes of Health, 6701 Democracy Boulevard, Democracy 1, Room 1076, Bethesda, MD 20892, 301–435–0814, lambert@mail.nih.gov. Name of Committee: National Center for Advancing Translational Sciences Special PO 00000 Frm 00066 Fmt 4703 Sfmt 4703 Emphasis Panel 2015 CTSA Application Review. Date: April 15–16, 2015. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Hilton Washington/Rockville 1750 Rockville Pike, Rockville, MD 20852. Contact Person: Guo He Zhang, Ph.D., MPH, Scientific Review Office, Office of Grants Management & Scientific Review, National Center for Advancing Translational Sciences (NCATS) National Institutes of Health, 6701 Democracy Boulevard, Democracy 1, Room 1064, Bethesda, MD 20892, 301–435–0812, zhanggu@ mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.350, B–Cooperative Agreements; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS). Dated: March 3, 2015. David Clary, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2015–05304 Filed 3–6–15; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Submission for OMB Review; 30-Day Comment Request Surveys and Interviews To Support an Evaluation of the Innovative Molecular Analysis Technologies (IMAT) Program (NCI) Under the provisions of section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH), has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below. This proposed information collection was previously published in the Federal Register on December 4, 2014, Vol. 79, Page 72004 and allowed 60-days for public comment. No public comments were received. The purpose of this notice is to allow an additional 30 days for public comment. The National Cancer Institute (NCI), National Institutes of Health, may not conduct or sponsor, and the respondent is not required to respond to, an SUMMARY: E:\FR\FM\09MRN1.SGM 09MRN1 12488 Federal Register / Vol. 80, No. 45 / Monday, March 9, 2015 / Notices information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number. Direct Comments to OMB: Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, OIRA_submission@ omb.eop.gov or by fax to 202–395–6974, Attention: NIH Desk Officer. Comment Due Date: Comments regarding this information collection are best assured of having their full effect if received within 30-days of the date of this publication. FOR FURTHER INFORMATION CONTACT: To obtain a copy of the data collection plans and instruments or request more information on the proposed project contact: Anthony Dickherber, NCI Center for Strategic Scientific Initiatives, 31 Center Drive, Rm10A33, Bethesda, MD 20892 or call non-toll-free number 301–547–9980 or Email your request, including your address to: dickherberaj@mail.nih.gov. Formal requests for additional plans and instruments must be requested in writing. Proposed Collection: Surveys and Interviews to Support an Evaluation of the Innovative Molecular Analysis Technologies (IMAT) Program (NCI), 0925–NEW, National Cancer Institute (NCI), National Institutes of Health (NIH). Need and Use of Information Collection: The purpose of the proposed evaluation is to pursue a comprehensive process and outcome assessment of the 15-year old Innovative Molecular Analysis Technologies (IMAT) program. While the program consistently offers promising indicators of success, the full program has not been evaluated since 2008, and never in as comprehensive a manner as has been formulated in the current evaluation plan. An outcome evaluation of the long-standing National Cancer Institute’s (NCI) IMAT program presents a rich and unique opportunity likely to serve institutes across the National Institutes of Health (NIH), and perhaps other federal agencies, considering the costs and benefits of directing resources towards supporting technology development. An award through the NIH Evaluation Set-Aside program to support this evaluation, for which NIH-wide relevance is a principle element of determining merit for support, is testament to this. The evaluation serves as an opportunity to gauge the impact of investments in technology development and also to assess the strengths and weaknesses of phased innovation award mechanisms. Like all institutes and centers (ICs) of the NIH, NCI seeks opportunities for improving their programs’ utility for the broad continuum of researchers, clinicians and ultimately patients. NCI Director Harold Varmus and other leadership across NCI, as well as the NCI Board of Scientific Advisors, will be the primary users of the evaluation results. Findings are primarily intended for considering the long-term strategy to support innovative technology development and how to more efficiently translate emerging capabilities through such technologies into the promised benefits for cancer research and clinical care. Interviews with grantees, program officers, review officers, and other NIH awardees make up a crucial component of the evaluation plan and will largely follow set survey protocols. Specific near-term aims include the use of this information to consider the utility of continued investment through existing solicitations and in strategic planning generally for institute support for innovative technology development. OMB approval is requested for 1 year. There are no costs to respondents other than their time. The total estimated annualized burden hours are 575. ESTIMATED ANNUALIZED BURDEN HOURS Number of respondents Form name Type of respondents IMAT Awardee Interview ............... Evaluation Web-based Survey ...... Tech End Users Interview ............. IMAT Awardees ............................................... IMAT Applicants and Other NIH Awardees ..... Technology End-Users .................................... Dated: February 23, 2015. Karla Bailey, NCI Project Clearance Liaison, National Institutes of Health. [FR Doc. 2015–05298 Filed 3–6–15; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES mstockstill on DSK4VPTVN1PROD with NOTICES Centers for Medicare & Medicaid Services [Document Identifier: CMS–10555] Agency Information Collection Activities: Proposed Collection; Comment Request Centers for Medicare & Medicaid Services, HHS. AGENCY: VerDate Sep<11>2014 18:04 Mar 06, 2015 Jkt 235001 ACTION: Number of responses per respondent Average burden per response (in hours) Total annual burden (in hours) 100 900 50 1 1 1 1 30/60 30/60 100 450 25 Notice. The Centers for Medicare & Medicaid Services (CMS) is announcing an opportunity for the public to comment on CMS’ intention to collect information from the public. Under the Paperwork Reduction Act of 1995 (the PRA), federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information (including each proposed extension or reinstatement of an existing collection of information) and to allow 60 days for public comment on the proposed action. Interested persons are invited to send comments regarding our burden estimates or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper SUMMARY: PO 00000 Frm 00067 Fmt 4703 Sfmt 4703 performance of the agency’s functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden. Comments must be received by May 8, 2015. ADDRESSES: When commenting, please reference the document identifier or OMB control number. To be assured consideration, comments and recommendations must be submitted in any one of the following ways: 1. Electronically. You may send your comments electronically to https:// www.regulations.gov. Follow the instructions for ‘‘Comment or DATES: E:\FR\FM\09MRN1.SGM 09MRN1

Agencies

[Federal Register Volume 80, Number 45 (Monday, March 9, 2015)]
[Notices]
[Pages 12487-12488]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-05298]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Submission for OMB Review; 30-Day Comment Request Surveys and 
Interviews To Support an Evaluation of the Innovative Molecular 
Analysis Technologies (IMAT) Program (NCI)

SUMMARY: Under the provisions of section 3507(a)(1)(D) of the Paperwork 
Reduction Act of 1995, the National Institutes of Health (NIH), has 
submitted to the Office of Management and Budget (OMB) a request for 
review and approval of the information collection listed below. This 
proposed information collection was previously published in the Federal 
Register on December 4, 2014, Vol. 79, Page 72004 and allowed 60-days 
for public comment. No public comments were received. The purpose of 
this notice is to allow an additional 30 days for public comment. The 
National Cancer Institute (NCI), National Institutes of Health, may not 
conduct or sponsor, and the respondent is not required to respond to, 
an

[[Page 12488]]

information collection that has been extended, revised, or implemented 
on or after October 1, 1995, unless it displays a currently valid OMB 
control number.
    Direct Comments to OMB: Written comments and/or suggestions 
regarding the item(s) contained in this notice, especially regarding 
the estimated public burden and associated response time, should be 
directed to the: Office of Management and Budget, Office of Regulatory 
Affairs, OIRA_submission@omb.eop.gov or by fax to 202-395-6974, 
Attention: NIH Desk Officer.
    Comment Due Date: Comments regarding this information collection 
are best assured of having their full effect if received within 30-days 
of the date of this publication.

FOR FURTHER INFORMATION CONTACT: To obtain a copy of the data 
collection plans and instruments or request more information on the 
proposed project contact: Anthony Dickherber, NCI Center for Strategic 
Scientific Initiatives, 31 Center Drive, Rm10A33, Bethesda, MD 20892 or 
call non-toll-free number 301-547-9980 or Email your request, including 
your address to: dickherberaj@mail.nih.gov. Formal requests for 
additional plans and instruments must be requested in writing.
    Proposed Collection: Surveys and Interviews to Support an 
Evaluation of the Innovative Molecular Analysis Technologies (IMAT) 
Program (NCI), 0925-NEW, National Cancer Institute (NCI), National 
Institutes of Health (NIH).
    Need and Use of Information Collection: The purpose of the proposed 
evaluation is to pursue a comprehensive process and outcome assessment 
of the 15-year old Innovative Molecular Analysis Technologies (IMAT) 
program. While the program consistently offers promising indicators of 
success, the full program has not been evaluated since 2008, and never 
in as comprehensive a manner as has been formulated in the current 
evaluation plan. An outcome evaluation of the long-standing National 
Cancer Institute's (NCI) IMAT program presents a rich and unique 
opportunity likely to serve institutes across the National Institutes 
of Health (NIH), and perhaps other federal agencies, considering the 
costs and benefits of directing resources towards supporting technology 
development. An award through the NIH Evaluation Set-Aside program to 
support this evaluation, for which NIH-wide relevance is a principle 
element of determining merit for support, is testament to this. The 
evaluation serves as an opportunity to gauge the impact of investments 
in technology development and also to assess the strengths and 
weaknesses of phased innovation award mechanisms.
    Like all institutes and centers (ICs) of the NIH, NCI seeks 
opportunities for improving their programs' utility for the broad 
continuum of researchers, clinicians and ultimately patients. NCI 
Director Harold Varmus and other leadership across NCI, as well as the 
NCI Board of Scientific Advisors, will be the primary users of the 
evaluation results. Findings are primarily intended for considering the 
long-term strategy to support innovative technology development and how 
to more efficiently translate emerging capabilities through such 
technologies into the promised benefits for cancer research and 
clinical care. Interviews with grantees, program officers, review 
officers, and other NIH awardees make up a crucial component of the 
evaluation plan and will largely follow set survey protocols. Specific 
near-term aims include the use of this information to consider the 
utility of continued investment through existing solicitations and in 
strategic planning generally for institute support for innovative 
technology development.
    OMB approval is requested for 1 year. There are no costs to 
respondents other than their time. The total estimated annualized 
burden hours are 575.

                                        Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
                                                                                          Average       Total
                                                            Number of      Number of     burden per     annual
             Form name               Type of respondents   respondents   responses per    response    burden (in
                                                                          respondent     (in hours)     hours)
----------------------------------------------------------------------------------------------------------------
IMAT Awardee Interview............  IMAT Awardees........          100               1            1          100
Evaluation Web-based Survey.......  IMAT Applicants and            900               1        30/60          450
                                     Other NIH Awardees.
Tech End Users Interview..........  Technology End-Users.           50               1        30/60           25
----------------------------------------------------------------------------------------------------------------


    Dated: February 23, 2015.
Karla Bailey,
NCI Project Clearance Liaison, National Institutes of Health.
[FR Doc. 2015-05298 Filed 3-6-15; 8:45 am]
 BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.